<DOC>
	<DOCNO>NCT00359450</DOCNO>
	<brief_summary>BMS-275183 give orally twice weekly patient pretreated locally advanced metastatic NSCLC show anti-tumor activity 3 separate cohort patient enrol : - Cohort I : Patients previously treat one taxane contain regimen . - Cohort II : Patients previously treat platinum base non-taxane contain regimen . - Cohort III : Patients previously treat chemotherapy regimen one EGFR-TKI ( epidermal growth factor receptor-tyrosine kinase inhibitor ) compound . Patients cohorts I II treat prior EGFR-TKI compound . Prior treatment VEGFR ( vascular endothelial growth factor receptor ) inhibitor compound allow patient provide VEGFR inhibitor also EGFR inhibitor .</brief_summary>
	<brief_title>Study BMS-275183 Patients With Pretreated Locally Advanced Metastatic NSCLC ( Non Small Cell Lung Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Men woman , age &gt; = 18 year Subjects histologically cytologically confirm locally advanced metastatic NSCLC fail one prior chemotherapy regimen . Concomitant medication cytochrome P450 ( CYP ) 3A4 inhibitor inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Locally advanced metastatic non-small cell lung cancer</keyword>
</DOC>